HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome

Nonmyeloablative, human leukocyte antigen (HLA) haploidentical, T-cell-replete bone marrow transplantation followed by high-dose posttransplantation cyclophosphamide (PT/Cy) has recently been developed. This transplantation milieu has resulted in favorable outcomes with low transplantation-related mortality, owing to a low incidence of graft-versus-host disease (GVHD), without increased infectious complications. However, the high relapse rate remains a major concern. We therefore performed a prospective pilot study of HLA haploidentical peripheral blood stem cell transplantation (PBSCT) with intensified conditioning, followed by two lower doses of PT/Cy.

Source: Experimental Hematology - August 15, 2015 Category: Hematology Authors: Hirohisa Nakamae, Hideo Koh, Takako Katayama, Mitsutaka Nishimoto, Yoshiki Hayashi, Yasuhiro Nakashima, Takahiko Nakane, Mika Nakamae, Asao Hirose, Masayuki Hino Source Type: research